Anti-Infectives · LP-037
Fluconazole Capsules
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-037Anti-Infectives
- Generic identity
- FluconazoleCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-037
- Generic identity
- Fluconazole
- Presentation
- Capsule
- Catalogue strength
- 50 mg; 150 mg; 200 mg
- Catalogue pack
- Blister 1, 4 or 10 capsules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: fluconazole.
- Dosage form: capsule.
- Proposed strengths: 50 mg, 150 mg and 200 mg.
- General pack-count list: blister 1, 4 or 10 capsules.
Layer 02 · Unresolved product-specific fields
- Strength-to-count/SKU mapping; pack counts are not cross-producted with all three strengths.
- Capsule shell/fill composition and exact product-specific excipients.
- Approved indication, dose/duration context, pregnancy/liver/QT/interactions and patient eligibility for each exact product.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 50 mg | Capsule | — | Catalogue also lists blister counts 1, 4 or 10; no strength-to-count mapping supplied | Do not infer three pack SKUs for this strength. |
| B | 150 mg | Capsule | — | Catalogue also lists blister counts 1, 4 or 10; no strength-to-count mapping supplied | Do not infer three pack SKUs for this strength. |
| C | 200 mg | Capsule | — | Catalogue also lists blister counts 1, 4 or 10; no strength-to-count mapping supplied | Do not infer three pack SKUs for this strength. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Fluconazole is a triazole antifungal used for particular susceptible fungal infections. Oral treatment can have effects throughout the body, so it has different interaction and safety considerations from a local skin cream. Species, infection site and immune status influence the clinical role. This educational ingredient profile is not an approved Luang Pharma indication, a claim of universal antifungal coverage or a recommendation for self-treatment.
Clinical context and therapeutic role
A clinician determines whether symptoms represent a fungal infection and whether an oral agent is appropriate. Recurrent infection, treatment failure or illness in an immunocompromised person may require microbiological investigation and specialist input. Some fungal species have reduced susceptibility. Pregnancy, liver and kidney function and interacting medicines should be reviewed before selection. A capsule strength or pack size does not determine the correct indication or a safe treatment plan.
Selected safety context
Fluconazole can cause liver injury, serious skin reactions and heart-rhythm effects. It also interacts with numerous medicines, including some anticoagulants, antiepileptics and other drugs affecting the QT interval. Pregnancy requires explicit professional review rather than assuming an oral antifungal is interchangeable with a topical option. Nausea and abdominal discomfort may occur. Jaundice, a blistering rash, fainting or signs of severe allergy require prompt medical assessment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes an oral capsule. Capsule shell, fill composition and release behavior are product-specific and are not established by the ingredient name. Opening a capsule or dispersing its contents should be considered only when the approved instructions or a pharmacist confirms that this is appropriate.
Retain the original labeled pack and check its integrity and expiry before use. Storage requirements must come from the supplied product information; no shelf life or temperature is inferred here. A pharmacist can advise on an alternative presentation if swallowing is difficult.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Fluconazole tablets — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 22 January 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-037.
Professional enquiries
Request product-specific evidence for LP-037.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.